Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model.
Rodent tumor cells engineered to secrete cytokines such as interleukin 2 (IL-2) or IL-4 are rejected by syngeneic recipients due to an enhanced antitumor host immune response. An adenovirus vector (AdCAIL-2) containing the human IL-2 gene has been constructed and shown to direct secretion of high levels of human IL-2 in infected tumor cells. AdCAIL-2 induces regression of tumors in a transgenic mouse model of mammary adenocarcinoma following intratumoral injection. Elimination of existing tumors in this way results in immunity against a second challenge with tumor cells. These findings suggest that adenovirus vectors expressing cytokines may form the basis for highly effective immunotherapies of human cancers.
Addison
C L
CL
Department of Biology, McMaster University, Hamilton, ON, Canada.
Braciak
T
T
Ralston
R
R
Muller
W J
WJ
Gauldie
J
J
Graham
F L
FL
D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002460:Cell Line; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000235:genetics*; D007700:Kinetics; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008822:Mice, Transgenic; D014407:Tumor Cells, Cultured
D007376:Interleukin-2